Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.65 |
| ▸ | CNR2 | P34972 | 2/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CASP6 | P55212 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126680 | 0.99 | FLT3 (0.90) | FLT3ALDH1A1HPGDMDM2KDM4E | |
| SCHEMBL8290415 | 0.99 | FLT3 (0.90) | FLT3ALDH1A1HPGDMDM2KDM4E | |
| SCHEMBL3914689 | 0.97 | FLT3 (0.92) | FLT3ALDH1A1HPGDMDM2KDM4E | |
| SCHEMBL8290403 | 0.97 | FLT3 (0.87) | FLT3ALDH1A1HPGDMDM2KDM4E | |
| SCHEMBL8288684 | 0.96 | FLT3 (0.90) | FLT3ALDH1A1HPGDMDM2KDM4E | |
| SCHEMBL3922474 | 0.96 | FLT3 (1.00) | FLT3ALDH1A1HPGDMDM2KDM4E | |
| SCHEMBL8289515 | 0.94 | FLT3 (0.87) | FLT3ALDH1A1HPGDMDM2KDM4E | |
| SCHEMBL5455726 | 0.94 | FLT3 (0.97) | FLT3ALDH1A1HPGDMDM2KDM4E | |
| SCHEMBL8288845 | 0.94 | FLT3 (0.97) | FLT3ALDH1A1HPGDMDM2KDM4E | |
| SCHEMBL5467649 | 0.93 | FLT3 (0.94) | FLT3ALDH1A1HPGDMDM2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-7696244-B2 | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-13 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070265316-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265316-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | CFTR, SLC47A1, SLC47A2 | FLT3 3065/4885ALDH1A1 1218/4885HPGD 1277/4885 |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FLT3 3509/4885ALDH1A1 1153/4885HPGD 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.